Discontinued — last reported Q3 '23
Ingersoll Rand Long-Term Debt - Fair Value decreased by 2.0% to $4.90B in Q1 2026 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $4.90B to $4.90B. Over 2 years (FY 2023 to FY 2025), Long-Term Debt - Fair Value shows an upward trend with a 33.6% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to book value may indicate rising interest rates or changes in credit risk, while a decrease may suggest favorable refinancing opportunities.
This represents the estimated market value of the company's long-term debt obligations if they were to be settled or tra...
Standard across large-cap pharmaceutical firms, often compared against total debt to assess interest rate sensitivity.
long_term_debt_fair_value| Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.70B | $2.80B | $2.80B | $4.90B | $5.10B | $4.90B | $4.90B | $4.90B | $5.00B | $5.00B | $4.90B |
| QoQ Change | — | +3.7% | +0.0% | +75.0% | +4.1% | -3.9% | +0.0% | +0.0% | +2.0% | +0.0% | -2.0% |
| YoY Change | — | — | — | — | +88.9% | +75.0% | +75.0% | +0.0% | -2.0% | +2.0% | +0.0% |